Journal
TUMOR BIOLOGY
Volume 39, Issue 3, Pages -Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1010428317695021
Keywords
Adenosine; cancer; CD73; dendritic cell; immunotherapy
Categories
Funding
- Tehran University of Medical Sciences [92-03-87-23034]
Ask authors/readers for more resources
Dendritic cells are important in initiating immune responses; therefore, a range of dendritic cell-based approaches have been established to induce immune response against cancer cells. However, the presence of immunosuppressive mediators such as adenosine in the tumor microenvironment reduces the efficacy of dendritic cell-based cancer immunotherapy. In this study, we investigated whether blockade of the A2A adenosine receptor with a selective antagonist and a CD73 inhibitor may increase the efficacy of a dendritic cell-based cancer vaccine. According to the findings, this therapeutic combination reduced tumor growth, prolonged survival of tumor-bearing mice, and enhanced specific antitumor immune responses. Thus, we suggest that targeting cancer-derived adenosine improves the outcomes of dendritic cell-based cancer immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available